contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


solar-foods-oyj-disclosure-under-chapter-9-section-10-of-the-securities-market-act-suomen-teollisuussijoitus-oy

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Solar Foods established in 2017 is a global leader in sustainable protein production, solving the global food production problem by offering a completely new alternative to existing animal and plant proteins.

Solar Foods’ first product is the naturally occurring single-cell protein Solein®, which can be used as a food raw material with high protein content. In the long run, Solein production will improve global availability of protein and increase price and quality stability of food raw materials by disconnecting food production from agriculture.

Thomas has written a new company report following the latest developments at Solar Foods.  The successful EUR 25m capital raise removes the liquidity risk that had been overshadowing Solar Foods, demonstrates the confidence of partners and investors in the 02 factory investment, and gives management much-needed room to maneuver in the commercialization of Solein. In our view, the capital raised and the confidence shown by strategic partners and investors in the 02 factory have improved Solar Foods’ chances of realizing an industrial-scale production facility. We have updated our forecasts to include the impact of the share issue, but otherwise our expectations remain unchanged. We reiterate our target price of EUR 5.3 and our Reduce recommendation.                   Inderes              Solar Foods: Likviditeettiriski väistyi, katseet toteuttamisessa - Inderes    Onnistunut 25 MEUR:n pääomakeräys poistaa Solar Foodsia varjostaneen likviditeettiriskin ja osoittaa luottamusta 02-tehdasinvestointia kohtaan.

Daniel and Thomas discussed Solar Foods in light of recent news.                    Inderes              Solar Foods: Rahoitus varmistettu - mitä seuraavaksi? - Inderes    Aika: 23.01.2026 klo 19.19 Solar Foods keräsi onnistuneesti 25 MEUR:n bruttovarat suunnatulla osakeannilla Factory 02 -tuotantolaitoksen rahoituksen varmistamiseksi. Mitä rahoituksen turvaaminen yhtiölle merkitsee ja mitkä ovat seuraavat askeleet...                             Topics: 00:00 Introduction  00:17 Share issue  02:10 Implementation of the directed offering  04:34 Factory 02 project  06:47 GEA as anchor investor and strategic partner  09:12 Next crucial steps  11:08 Commercialization development  13:38 Investment profile

AI went through your link and had this to say. I don’t have the expertise myself. Is there anything negative in this? A negative perspective can only be found in certain scenarios, and they mostly arise in discussions (e.g., on the Inderes forum or other places):   Risk of hemoglobin or iron overload (e.g., hemochromatosis, hereditary iron storage disease): For healthy men (and postmenopausal women), iron requirements are low (as noted in the report: 6 mg EAR / 8 mg RDA), so if Solein is used in large quantities (e.g., 20–30 g of protein per serving → ~25–40 g of Solein is needed, resulting in 27–44 mg of iron), it can exceed the daily upper limit (UL 40–45 mg/day for adults) in just one serving. This is a risk for the few who have a genetic predisposition to accumulate too much iron – but it applies to a very small part of the population (not a common problem in Finland).   Absorption: Not all iron in Solein is as well-absorbed as heme iron from meat (estimated heme iron share ~5% in some discussions), but it is still non-heme iron, which is enhanced by Vitamin C etc. Still, a large dose can lead to high intake.   In practice: If Solein is used moderately (e.g., 10–20 g/day in products), the iron intake remains at 11–22 mg, which is perfectly safe for most and even beneficial for many (especially women, vegetarians, athletes).   In summary: The previous answer emphasized the low iron requirement in men (6–8 mg/day for balance), but Solein’s high iron content is not “negative” in general – it is a strength for most users and a marketing asset. It can only be negative for those who already have high iron stores (high ferritin) or a hereditary sensitivity to iron overload. For most Finns (where iron deficiency occurs more frequently than overload), it is a plus.

In a comment I wrote in this thread, I have linked to a very extensive scientific study on iron (and other trace elements):   A source doesn’t get much more authoritative than that. Edit. Apparently that link to the book is broken. I’m linking directly to the section of the book where iron is discussed. https://www.nationalacademies.org/read/10026/chapter/11 I recommend reading facts from research rather than just asking AI, as long as there is literature/research available on the subject. AI is prone to hallucinating all sorts of things.

Intake recommendations refer to the amount of iron consumed. Not the amount absorbed. This is because so many factors affect absorption, ranging from individual differences to the substance consumed. In other words, the limit considered safe for consuming iron is that 45mg/day.

Everyone can take that iron issue however they like… It’s true that Solein contains a lot of iron. Solein has 110mg of iron/100g, and the upper limit for safe daily intake is 45mg, which is about 50g of Solein. But because Solein contains poorly absorbed non-heme iron, only about 10% is absorbed, so the upper limit for safe daily intake would actually be 500g. When you consider that Solein isn’t intended to be eaten as is, but replaces proteins in various food products, you could assume that a finished food product contains only one-fifth pure Solein, meaning you could eat 2500g of the finished product per day. Since a person’s diet usually consists of many other foods besides just Solein-based ones, I wouldn’t see a direct problem with iron intake from these finished products.

Iron is also consumed from a jar. Great to have two power properties in the product. Protein+iron.

Solar Foods

Solar Foods Oyj, Company announcement 28 January 2026 at 18:30 EETSolar Foods Oyj: Disclosure under chapter 9, section 10 of the Securities Market Act (Suomen Teollisuussijoitus Oy)Solar Foods...

Solar Foods Oyj, Company announcement 28 January 2026 at 18:30 EETSolar Foods Oyj: Disclosure under chapter 9, section 10 of the Securities Market Act (Suomen Teollisuussijoitus Oy)Solar Foods Oyj has received an announcement from Suomen Teollisuussijoitus Oy on 28 January 2026. According to the announcement, the total number of shares owned by Suomen Teollisuussijoitus Oy in Solar Foods Oyj has fallen below the 5% threshold as a result of an event on January 26, 2026, that changed the breakdown of shares or voting rights.Total position of Suomen Teollisuussijoitus Oy according to the notification:&nbsp;<table><tbody><tr><td>&nbsp;</td><td align="right">% of shares and voting rights</td><td align="right">% of shares and voting rights through financial instruments</td><td align="right">Total of both in %</td><td align="right">Total number of shares and voting rights of issuer</td></tr><tr><td>Resulting situation on the date on which threshold was crossed or reached</td><td align="right">4.825%</td><td align="right">&nbsp;</td><td align="right">4.825%</td><td align="right">29,883,733</td></tr><tr><td>Position of previous notification (if applicable)</td><td align="right">&nbsp;</td><td align="right">&nbsp;</td><td align="right">&nbsp;</td><td align="right">&nbsp;</td></tr></tbody></table>Notified details of the resulting situation on the date on which the threshold was crossed or reached:<table><tbody><tr><td>&nbsp;</td><td align="right" colspan="2">Number of shares and voting rights</td><td align="right" colspan="2">% of shares and voting rights</td></tr><tr><td>Class/type of shares ISIN code</td><td align="right">Direct (SMA 9:5)</td><td align="right">Indirect (SMA 9:6 and 9:7)</td><td align="right">Direct (SMA 9:5)</td><td align="right">Indirect (SMA 9:6 and 9:7)</td></tr><tr><td>FI4000577192</td><td align="right">1,441,910</td><td align="right">&nbsp;</td><td align="right">4.825%</td><td align="right">&nbsp;</td></tr><tr><td>SUBTOTAL</td><td align="right" colspan="2">1,441,910</td><td align="right" colspan="2">4.825%</td></tr></tbody></table>Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.Further Information CFO Ilkka Saura, ilkka.saura@solarfoods.com, tel: +358 10 579 3289Certified Advisor DNB Carnegie Investment Bank AB (publ)About Solar Foods Solar Foods produces Solein®, a protein created using carbon dioxide and electricity. This innovative production method is independent of weather and climate conditions, eliminating the need for traditional agriculture. Founded in Finland in 2017, Solar Foods is listed on the Nasdaq First North Growth Market Finland. Learn more at <a href="https://solarfoods.com/">https://solarfoods.com/</a> and <a href="https://investors.solarfoods.com/en">investors.solarfoods.com</a>.

	% of shares and voting rights	% of shares and voting rights through financial instruments	Total of both in %	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	4.825%		4.825%	29,883,733
Position of previous notification (if applicable)

	Number of shares and voting rights		% of shares and voting rights
Class/type of shares ISIN code	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
FI4000577192	1,441,910		4.825%
SUBTOTAL	1,441,910		4.825%